Account-based marketing vs the traditional approach: what actually beats what for healthcare and life sciences
A head-to-head on account-based marketing versus the incumbent approach — where each wins, where each loses, and how to combine them. Written for commercial leaders at healthtech, medtech, and life-sciences companies.
This edition is written for commercial leaders at healthtech, medtech, and life-sciences companies. In healthcare and life sciences, healthcare buyers move under regulatory constraint and reward domain-specific messaging, so the way you install account-based marketing has to reflect that reality from day one.
The debate about account-based marketing is often framed as replacement — new model wipes out old. That framing is wrong. The right question is where each approach wins.
Account-based marketing wins on speed of learning, targeting precision, and cost per outcome. It is concentrating marketing on a named list of accounts with tailored plays, and it compounds in ways the traditional approach cannot match.
The traditional approach wins on relationship depth, brand consistency, and situations where the buyer has already self-identified. Ignoring that is why some teams' first account-based marketing attempt underperforms — they replace the wrong parts.
The binding constraint we see in healthcare and life sciences is almost always regulated-sale cycle length, not intent. Account-based marketing is only useful in this vertical when it is pointed at that constraint — not at a generic growth number borrowed from another category.
Combine them deliberately. Use account-based marketing to find and qualify; use the traditional approach to close and expand. The seam between them is where most pipeline is lost or won.
Metric to watch when running both: pipeline created inside the named-account list, plus source attribution. The two approaches should not cannibalise each other; if they do, your handoff is broken.
The failure mode of running both is confusing ABM with lead scoring on inbound MQLs — usually because the traditional team feels threatened and the new model is starved of context.
Companies that get this right end up with a hybrid engine that outperforms either pure model. Companies that pick one and evangelise it lose to the ones that combine.
Concretely for healthcare and life sciences: the healthcare teams that install this get past procurement instead of dying in it. That is the reason it is worth installing account-based marketing properly rather than half-heartedly across three vendors.
Frequently asked questions
ABM · healthcare — answered
- Does account-based marketing work for healthcare and life sciences?
- Yes — provided it is aimed at regulated-sale cycle length, not intent rather than a generic growth number. The healthcare teams that install this get past procurement instead of dying in it.
- Is account-based marketing a replacement for the traditional approach?
- No — the two combine. Use the new model to find and qualify, the traditional model to close and expand.
- Where does the traditional approach still win?
- Relationship depth, brand-critical moments, and already-warm buyers.
- How do I run both without conflict?
- Clear handoff at a defined stage, shared metrics, and no source-based commissions that create tribal loyalty.
- What is the failure mode of combining them?
- Confusing ABM with lead scoring on inbound MQLs — usually a broken handoff or a threatened incumbent team.
- What is the healthcare specific pitfall with account-based marketing?
- Running the generic playbook without adapting to healthcare buyers move under regulatory constraint and reward domain-specific messaging. The install has to be vertical-first.
Growth Broker editorial
Filed under abm · healthcare